Centrexion Therapeutics to Present at the 19th Annual BIO CEO & Investor Conference

BOSTON–(BUSINESS WIRE)– Centrexion Therapeutics, a company focused on advancing the treatment
of chronic pain with one of the largest exclusively pain-focused
pipelines of non-opioid therapies in active development, today announced
its participation in the 19^th Annual BIO CEO & Investor
Conference taking place February 13-14 at the Waldorf Astoria hotel in
New York City.

• Monday, February 13, 2017 at 10:15 a.m. ET – Centrexion Therapeutics
  company presentation
• Monday, February 13, 2017 at 1:30 p.m. ET – Jeffery B. Kindler, CEO of
  Centrexion Therapeutics, will participate on a panel entitled “Next
  Generation Pain Control: Beyond Opioids”

Notably, Centrexion Therapeutics will be recognized at the conference as
a Buzz of BIO winner in the “Private Therapeutics Biotech” category.
Nominated and selected by an online vote, the winners are recognized as
innovative and “buzzworthy” companies at the conference.

About Centrexion Therapeutics

Centrexion Therapeutics, Corp. is focused on advancing the treatment
of chronic moderate to severe pain with one of the largest exclusively
pain-focused pipelines of non-opioid therapies in active development.
Centrexion Therapeutics recognizes the needs of over a quarter of a
billion patients living with chronic pain worldwide, and aims to develop
new, safer and more effective therapies that overcome the limitations
and challenges associated with current pain treatments. Founded by
world-renowned leaders in drug development and well-funded by key
investors, Centrexion Therapeutics is building a pain treatment
powerhouse to address the substantial and growing global chronic pain
epidemic. Centrexion Therapeutics has recently relocated from Baltimore,
Md. to Boston, Mass.

For more information about Centrexion Therapeutics, visit http://www.centrexion.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170209005508/en/